KR20240162588A - Cd3 및 bcma에 대한 항체, 및 이로부터 제조된 이중특이적 결합 단백질 - Google Patents

Cd3 및 bcma에 대한 항체, 및 이로부터 제조된 이중특이적 결합 단백질 Download PDF

Info

Publication number
KR20240162588A
KR20240162588A KR1020247036665A KR20247036665A KR20240162588A KR 20240162588 A KR20240162588 A KR 20240162588A KR 1020247036665 A KR1020247036665 A KR 1020247036665A KR 20247036665 A KR20247036665 A KR 20247036665A KR 20240162588 A KR20240162588 A KR 20240162588A
Authority
KR
South Korea
Prior art keywords
ser
thr
val
gly
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247036665A
Other languages
English (en)
Korean (ko)
Inventor
쳉빈 우
단칭 우
리니 후앙
아민 장
젠그롱 슈아이
루이 장
시용 공
쑤언 우
Original Assignee
상하이 에피맙 바이오테라퓨틱스 컴퍼니, 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 상하이 에피맙 바이오테라퓨틱스 컴퍼니, 리미티드 filed Critical 상하이 에피맙 바이오테라퓨틱스 컴퍼니, 리미티드
Publication of KR20240162588A publication Critical patent/KR20240162588A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
KR1020247036665A 2019-11-26 2020-11-26 Cd3 및 bcma에 대한 항체, 및 이로부터 제조된 이중특이적 결합 단백질 Pending KR20240162588A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
CNPCT/CN2019/120991 2019-11-26
CN2019120991 2019-11-26
CN2020111796 2020-08-27
CNPCT/CN2020/111796 2020-08-27
KR1020227021084A KR20220104783A (ko) 2019-11-26 2020-11-26 Cd3 및 bcma에 대한 항체, 및 이로부터 제조된 이중특이적 결합 단백질
PCT/CN2020/131767 WO2021104371A1 (en) 2019-11-26 2020-11-26 Antibodies to cd3 and bcma, and bispecific binding proteins made therefrom

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020227021084A Division KR20220104783A (ko) 2019-11-26 2020-11-26 Cd3 및 bcma에 대한 항체, 및 이로부터 제조된 이중특이적 결합 단백질

Publications (1)

Publication Number Publication Date
KR20240162588A true KR20240162588A (ko) 2024-11-15

Family

ID=76130007

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020247036665A Pending KR20240162588A (ko) 2019-11-26 2020-11-26 Cd3 및 bcma에 대한 항체, 및 이로부터 제조된 이중특이적 결합 단백질
KR1020227021084A Pending KR20220104783A (ko) 2019-11-26 2020-11-26 Cd3 및 bcma에 대한 항체, 및 이로부터 제조된 이중특이적 결합 단백질

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020227021084A Pending KR20220104783A (ko) 2019-11-26 2020-11-26 Cd3 및 bcma에 대한 항체, 및 이로부터 제조된 이중특이적 결합 단백질

Country Status (11)

Country Link
US (1) US20230002489A1 (https=)
EP (2) EP4483895A3 (https=)
JP (2) JP7773466B2 (https=)
KR (2) KR20240162588A (https=)
CN (1) CN114728065A (https=)
AU (2) AU2020390288A1 (https=)
CA (1) CA3160163A1 (https=)
IL (2) IL293138A (https=)
MX (2) MX2022006230A (https=)
TW (1) TWI774137B (https=)
WO (1) WO2021104371A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10519251B2 (en) * 2013-12-30 2019-12-31 Epimab Biotherapeutics, Inc. Fabs-in-tandem immunoglobulin and uses thereof
EP4200336A4 (en) * 2020-08-24 2024-09-25 Epimab Biotherapeutics (HK) Limited Anti-ror1 antibodies and related bispecific binding proteins
EP4413044A4 (en) * 2021-10-07 2025-10-22 Nat Res Council Canada ANTI-CD3 MONOCLONAL ANTIBODIES AND THERAPEUTIC CONSTRUCTS
CN117003871A (zh) 2022-04-28 2023-11-07 北京天广实生物技术股份有限公司 结合bcma和cd3的抗体及其用途
TW202413405A (zh) * 2022-07-13 2024-04-01 美商翰森生物有限責任公司 抗體、其抗原結合片段及其藥物用途
WO2024074145A1 (zh) * 2022-10-08 2024-04-11 盛禾(中国)生物制药有限公司 一种结合baffr和cd3的双特异性抗体及其应用
EP4640700A1 (en) * 2022-12-19 2025-10-29 Harbour Biomed (Shanghai) Co., Ltd "kappa/lambda" fab-fab series-connection multi-specific binding protein, preparation thereof, and use thereof
AU2024279278A1 (en) 2023-05-31 2025-12-18 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
CN117024596B (zh) * 2023-08-18 2024-02-27 镜像绮点(上海)细胞技术有限公司 肿瘤原代细胞特异性标记与活体成像
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025131075A1 (zh) * 2023-12-21 2025-06-26 上海君实生物医药科技股份有限公司 抗cd3和抗cd3多特异性抗体及用途
WO2025168059A1 (zh) * 2024-02-08 2025-08-14 天劢源和生物医药（上海）有限公司 靶向bcma、cd19和cd3的多特异性抗原结合蛋白及其应用
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
DK2314629T4 (da) 2002-07-18 2023-02-06 Merus Nv Rekombinant produktion af blandinger af antistoffer
EP1940881B1 (en) 2005-10-11 2016-11-30 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
KR101972446B1 (ko) * 2011-05-27 2019-04-25 글락소 그룹 리미티드 Ｂｃｍａ（ｃｄ２６９／ｔｎｆｒｓｆ１７）­결합 단백질
WO2014122143A1 (en) * 2013-02-05 2014-08-14 Engmab Ag Method for the selection of antibodies against bcma
IL263466B2 (en) * 2013-12-17 2023-10-01 Genentech Inc Anti-CD3 antibodies and methods of using them
US10519251B2 (en) * 2013-12-30 2019-12-31 Epimab Biotherapeutics, Inc. Fabs-in-tandem immunoglobulin and uses thereof
EP2982692A1 (en) * 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP3023437A1 (en) * 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
TWI703159B (zh) * 2015-04-13 2020-09-01 美商輝瑞股份有限公司 Bcma特異性治療性抗體及其用途
EP3916018A1 (en) * 2015-06-16 2021-12-01 Genentech, Inc. Anti-cd3 antibodies and methods of use
US11421028B2 (en) * 2016-02-06 2022-08-23 Epimab Biotherapeutics, Inc. Fabs-in-tandem immunoglobulin and uses thereof
JP7033328B2 (ja) * 2016-08-16 2022-03-10 エピムアブ バイオセラピューティクス インコーポレイテッド 一価の非対称タンデムＦａｂ二重特異性抗体
WO2018224441A1 (en) * 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-cd3 antibodies
KR102820804B1 (ko) * 2017-09-22 2025-06-16 우시 바이올로직스 아일랜드 리미티드 신규한 이중특이적 cd3/cd19 폴리펩티드 복합체
JP2021508479A (ja) * 2017-12-27 2021-03-11 テネオバイオ， インコーポレイテッド ヘテロ二量体特異的抗体上のｃｄ３デルタ及びｃｄ３イプシロン
EP3788079A4 (en) * 2018-05-03 2022-12-21 Shanghai Epimab Biotherapeutics Co., Ltd. ANTIBODIES WITH HIGH AFFINITY TO PD-1 AND LAG-3 AND BI-SPECIFIC BINDING PROTEINS PRODUCTION THEREOF
UA130542C2 (uk) * 2018-05-16 2026-03-18 Янссен Байотек, Інк. Антитіло до cd38 та терапевтичний засіб, який перенаправляє т-клітини, для лікування множинної мієломи у суб'єкта

Also Published As

Publication number Publication date
EP4065164A4 (en) 2024-03-27
AU2020390288A1 (en) 2022-05-26
TWI774137B (zh) 2022-08-11
JP2025011311A (ja) 2025-01-23
CN114728065A (zh) 2022-07-08
IL316618A (en) 2024-12-01
IL293138A (en) 2022-07-01
EP4483895A2 (en) 2025-01-01
WO2021104371A1 (en) 2021-06-03
MX2022006230A (es) 2022-06-22
KR20220104783A (ko) 2022-07-26
AU2024278367A1 (en) 2025-01-09
JP7773466B2 (ja) 2025-11-19
EP4483895A3 (en) 2025-05-28
TW202132347A (zh) 2021-09-01
JP2023504016A (ja) 2023-02-01
US20230002489A1 (en) 2023-01-05
EP4065164A1 (en) 2022-10-05
JP7847630B2 (ja) 2026-04-17
CA3160163A1 (en) 2021-06-03
MX2024013229A (es) 2024-12-06

Similar Documents

Publication Publication Date Title
JP7847630B2 (ja) Ｃｄ３およびｂｃｍａに対する抗体およびそれらから作製した二重特異性結合タンパク質
JP7781859B2 (ja) 抗ｒｏｒ１抗体及び関連の二重特異性結合タンパク質
US12060425B2 (en) High affinity antibodies to PD-1 and LAG-3 and bispecific binding proteins made therefrom
US20250282881A1 (en) Antibodies and bispecific binding proteins that bind ox40 and/or pd-l1
US20240269276A1 (en) Specific binding protein targeting pd-l1 and cd73
RU2852663C1 (ru) Антитела против cd3 и bcma и биспецифичные связывающие белки, полученные из них
WO2022228545A1 (en) Antibodies and variants thereof against human 4-1bb
HK40067877A (en) Antibodies to cd3 and bcma, and bispecific binding proteins made therefrom
RU2782381C2 (ru) Высокоаффинные анти-pd-1 и анти-lag-3 антитела и полученные из них биспецифические связывающие белки
BR122025002178A2 (pt) Anticorpos para cd3 e bcma, e proteínas de ligação biespecíficas feitas a partir dos mesmos

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20241101

Application number text: 1020227021084

Filing date: 20220621

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20241128

Comment text: Request for Examination of Application